Adaptive Biotechnologies

adaptivebiotech.com

Adaptive Biotechnologies is a commercial-stage company pioneering Immune Medicine by leveraging the adaptive immune system to enhance disease diagnosis and treatment. Their flagship product, clono SEQ®, is an FDA-authorized clinical diagnostic test for detecting and monitoring minimal residual disease in blood cancer patients. The company focuses on translating immune data into actionable insights for clinical applications, thereby positioning itself as a leader in the emerging field of immune-driven medicine. Founded in 2009 and based in Seattle, Adaptive Biotechnologies is at the forefront of innovation in immunology, with a strong commitment to improving patient outcomes through advanced diagnostics and therapeutics.